arsenic trioxide has been researched along with Central Nervous System Neoplasm in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, J; Christ, TN; Churpek, JE; Curran, E; Godley, LA; Larson, RA; Liu, H; Odenike, T; Osman, AEG; Stock, W; Thirman, MJ | 1 |
| Cao, F; Lan, W; Li, D; Li, J; Li, L; Li, Y; Liu, X; Meng, R; Shi, C; Wang, H; Yang, B; Zhang, Y; Zhang, Z; Zhao, H; Zhou, J | 1 |
| Kurokawa, M; Nagai, S; Takahashi, T | 1 |
| Ambaglio, I; Bernasconi, P; Castagnola, C; Corso, A; Lazzarino, M; Rossi, M; Zappasodi, P | 1 |
| Chen, SJ; Chen, Z; Li, JM; Mi, JQ; Shen, ZX | 1 |
| Augustyniak, C; Evens, AM; Gordon, LI; Gupta, R; Mehta, J; Ziegler, SL | 1 |
3 review(s) available for arsenic trioxide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Treatment of Acute Promyelocytic Leukemia in Adults.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Central Nervous System Neoplasms; Clinical Trials as Topic; Consolidation Chemotherapy; Disease Management; Drug Administration Schedule; Expert Testimony; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Neoplasm Grading; Neoplasm Staging; Tretinoin | 2018 |
Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Central Nervous System Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2009 |
How to manage acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Central Nervous System Neoplasms; Consolidation Chemotherapy; Drug Synergism; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Oxides; Recurrence; Tretinoin | 2012 |
1 trial(s) available for arsenic trioxide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Blood-Brain Barrier; Central Nervous System Neoplasms; Child; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Mannitol; Middle Aged; Oxides; Recurrence; Remission Induction; Young Adult | 2014 |
2 other study(ies) available for arsenic trioxide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Central Nervous System; Central Nervous System Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Meningeal Neoplasms; Oxides; Recurrence; Treatment Outcome | 2011 |
Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Central Nervous System Neoplasms; Diphtheria Toxin; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Interferons; Interleukin-2; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Oxides; Recombinant Fusion Proteins; Recurrence; Remission Induction; Transplantation, Homologous; Zidovudine | 2007 |